LeukemiaMYELOMONO-3NCT07512882
Cohort of Patients With Chronic Myelomonocytic Leukemia
An observational study of Leukemia and Myelomonocytic Leukemia, Chronic, run by Gustave Roussy, Cancer Campus, Grand Paris at 24 sites in France.
Trial summary
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Leukemia, Myelomonocytic Leukemia, Chronic
- What is being tested?
- Sampling
- How many people
- 5,000 participants
- Where
- 24 sitesFrance
- Study dates
- 5 May 2026to Mar 2040
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cohort of Patients With Chronic Myelomonocytic Leukemia
Who may be able to join
- Adults aged 18 years and over
- Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
- Confirmed diagnosis of chronic myelomonocytic leukemia
- Regardless of stage (chronic or transformed), and whether or not currently being treated
- Signed informed consent
Who cannot join
- Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
- Refusal informed consent
Trial locations and contacts
24 sites in 1 country. Contact the study team or a site near you to ask about taking part.
24 sites in 1 country
France24 sites, 24 recruiting
- Not yet recruiting
CHU Amiens Picardie
Amiens, 80054
Delphine LEBON, lebon.delphine@chu-amiens.fr
- Not yet recruiting
CHU Angers
Angers, 49933
Sylvain THEPOT, Sylvain.thepot@chu-angers.fr
- Not yet recruiting
Hôpital Privé Antony
Antony, 92160
Alexandre MOREL, dr.alexandre.morel@haimatos.org
- Not yet recruiting
AP-HP Hôpital Avicenne
Bobigny, 93000
Thorsten BRAUN, thorsten.braun@aphp.fr
- Not yet recruiting
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91106
Guillemette FOUQUET, guillemette.fouquet@chsf.fr
- Not yet recruiting
CHU Grenoble
Grenoble, 38000
Sophie PARK, Spark@chu-grenoble.fr
- Not yet recruiting
AP-HP Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270
Laurence LEGROS, Laurence.legros@aphp.fr
- Not yet recruiting
CHRU Lille Hôpital Claude Huriez
Lille, 59037
Laure GOURSAUD, Laure.goursaud@chu-lille.fr
- Not yet recruiting
CHU Limoges
Limoges, 87042
Marie-Pierre GOURIN, Marie-pierre.gourin@chu-limoges.fr
- Not yet recruiting
CHU Nantes
Nantes, 44093
Alice GARNIER, Alice.garnier@chu-nantes.fr
- Not yet recruiting
CHU Nice Hôpital l'Archet 1
Nice, 06202
Thomas CLUZEAU, Cluzeau.t@chu-nice.fr
- Not yet recruiting
Groupe Hospitalo-Universitaire Caremeau Institut de Cancérologie du Gard
Nîmes, 30029
Samy CHRAIBI, Samy.chraibi@chu-nimes.fr
- Not yet recruiting
AP-HP Hôpital Saint-Antoine
Paris, 75012
Jérôme HADJADJ, jerome.hadjadj@aphp.fr
- Not yet recruiting
AP-HP Hôpital Cochin
Paris, 75014
Rudy BIRSEN, Rudy.birsen@aphp.fr
- Not yet recruiting
AP-HP Hôpital Necker
Paris, 75015
Julien ROSSIGNOL, julien.rossignol@aphp.fr
- Not yet recruiting
AP-HP Hôpital Saint-Louis
Paris, 75475
Raphael ITZYKSON, Raphael.itzykson@aphp.fr
Pierre FENAUX, Pierre.fenaux@aphp.fr
- Not yet recruiting
CHU Bordeaux
Pessac, 33604
Sophie DIMICOLI-SALAZAR, sophie.dimicoli-salazar@chu-bordeaux.fr
- Not yet recruiting
CHU Poitiers
Poitiers, 86000
Jose Miguel TORREGROSA-DIAZ, Jose-miguel.torregrosa-diaz@inserm.fr
- Not yet recruiting
Centre Henri Becquerel
Rouen, 76038
Aspasia STAMATOULLAS-BASTARD, Aspasia.stamatoullas@chb.unicancer.fr
- Not yet recruiting
Centre Hospitalier Saint-Brieuc Hôpital Yves Le Foll
Saint-Brieuc, 22000
Thomas NIVET, Thomas.nivet@armorsante.bzh
- Not yet recruiting
CHU Toulouse
Toulouse, 31059
Thibault COMONT, Comont.thibault@iuct-oncopole.fr
- Not yet recruiting
CHU Tours
Tours, 37044
Emmanuel GYAN, e.gyan@chu-tours.fr
- Not yet recruiting
CHRU Nancy Brabois
Vandœuvre-lès-Nancy, 54511
Maud D'AVENI PINEY, m.daveny-piney@chru-nancy.fr
- Recruiting
Gustave Roussy
Villejuif, 94805
Christophe WILLEKENS, Christophe.willekens@gustaveroussy.fr
About this study
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data.
Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
- Conditions
- Leukemia, Myelomonocytic Leukemia, Chronic
- Being tested
- Sampling
- Medical subject headings
- Leukemia, Leukemia, Myelomonocytic, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SamplingBiological
Blood samples taken as part of a scheduled assessment within the context of medical care
- Standard sample: 2 x 10 mL EDTA tubes
- For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care
- Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).
| Study group | Role | What they receive |
|---|---|---|
| Cohort of patients with chronic myelomonocytic leukemia | Not described Receives: Biological: Sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Understanding the pathophysiology of chronic myelomonocytic leukaemia
optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials
Measured: through study completion, an average of 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2026
- Study start5 May 2026
- Primary completionMar 2040 (estimated)
- Study completionMar 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- More trials run by Gustave Roussy, Cancer Campus, Grand ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07512882
- Sponsor's protocol ID
- 2025-A02438-41
- Other IDs
- CSET number 2025/4169
- Acronym
- MYELOMONO-3
- Status last verified
- May 2026
- First submitted
- 27 Mar 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cohort of Patients With Chronic Myelomonocytic Leukemia
- ClinicalTrials.gov ID
- NCT07512882
- Acronym / sponsor ID
- MYELOMONO-3 / 2025-A02438-41
- Conditions
- Leukemia, Myelomonocytic Leukemia, Chronic
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisUniversity, hospital or other
- Study start
- 5 May 2026 (actual)
- Primary completion
- Mar 2040 (estimated)
- Study completion
- Mar 2040 (estimated)
- First posted
- 6 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data.
Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort of patients with chronic myelomonocytic leukemia | – | Biological: Sampling |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cohort of Patients With Chronic Myelomonocytic Leukemia
Key inclusion criteria (5 listed)
- Adults aged 18 years and over
- Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
- Confirmed diagnosis of chronic myelomonocytic leukemia
- Regardless of stage (chronic or transformed), and whether or not currently being treated
- Signed informed consent
Key exclusion criteria (2 listed)
- Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
- Refusal informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SamplingBlood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue). | Biological | Cohort of patients with chronic myelomonocytic leukemia |
Primary outcome
Understanding the pathophysiology of chronic myelomonocytic leukaemia
Time frame: through study completion, an average of 15 years
optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
Related trials for Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
24 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Leukemia and Myelomonocytic Leukemia, Chronic, run by Gustave Roussy, Cancer Campus, Grand Paris at 24 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 24 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christophe WILLEKENS (+33 1 42 11 23 79, Christophe.willekens@gustaveroussy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Understanding the pathophysiology of chronic myelomonocytic leukaemia (time frame: through study completion, an average of 15 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.